Toronto, ON – Dalton Pharma Services, a privately owned Canadian pharmaceutical services company, says it has completed a new state-of-art oligonucleotide production suite.
The company’s president and CEO, Peter Pekos, says that the company’s 17-year history in oligonucleotide manufacture and analysis, is allowing it to use its expertise in synthesis and manufacturing of antisense oligonucleotides and their analogs to produce cGMP grade oligonucleotides as required for human clinical testing.
“Combining GMP synthesis of oligonucleotides and sterile fill puts us at the forefront of providing drug development solutions that accelerate our client’s discovery, pre-clinical and clinical programs,” he says. “Dalton’s capabilities in small molecule and therapeutic peptide manufacture, combined with this expansion into antisense therapeutic synthesis and oligonucleotides for diagnostic applications, allows us to extend our reach and participate in the success of more companies and products.”
He adds that the production suite is equipped with the latest technology that allows small to large scale oligo production and purification capabilities. Special controls, including environmental (such as HEPA filtered air) and manufacturing controls have been implemented. New equipment includes 4 AKTA OligoPilots each capable of producing oligos from 500 umole to 50g scale of oligo per run. Purification is achieved using Waters preparative HPLC’s utilizing either reverse phase or ion-exchange chromatographic techniques.